6,6-dimethyl-4H,6H-furo[3,4-c][1,2,5]oxadiazol-4-one | 73314-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6,6-dimethyl-4H,6H-furo[3,4-c][1,2,5]oxadiazol-4-one
• 英文别名: 6,6-Dimethyl-4H,6H-furo[3,4-c][1,2,5]oxadiazol-4-one；4,4-dimethylfuro[3,4-c][1,2,5]oxadiazol-6-one
• CAS: 73314-60-0
• 化学式: C₆H₆N₂O₃
• 分子量: 154.125
• InChiKey: SBFJXPYJBJPFDT-UHFFFAOYSA-N

物化性质

• 沸点：
  301.7±52.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

反应信息

• 作为反应物：
  描述：

  6,6-dimethyl-4H,6H-furo[3,4-c][1,2,5]oxadiazol-4-one 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 生成 4-(1-hydroxy-1-methyl-ethyl)-furazan-3-carboxylic acid amide
  参考文献：
  名称：

  Tetronic Acids and Derivatives; Part VI¹. A Convenient Synthesis of New 4-Oxo-2-phenyl-2H-4,6-dihydrofuro[3,4-d]triazole and 4-Oxo-4,6-dihydrofuro[3,4-c]furazan Systems

  摘要：

  DOI：

  10.1055/s-1979-28898
• 作为产物：
  描述：

  3,4-bis(hydroxyimino)-5,5-dimethyldihydrofuran-2(3H)-one 在 氯化亚砜 作用下， 以 1,4-二氧六环 为溶剂， 生成 6,6-dimethyl-4H,6H-furo[3,4-c][1,2,5]oxadiazol-4-one
  参考文献：
  名称：

  Tetronic Acids and Derivatives; Part VI¹. A Convenient Synthesis of New 4-Oxo-2-phenyl-2H-4,6-dihydrofuro[3,4-d]triazole and 4-Oxo-4,6-dihydrofuro[3,4-c]furazan Systems

  摘要：

  DOI：

  10.1055/s-1979-28898

文献信息

• [EN] IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17<br/>[FR] IMIDAZOPYRIDAZINES EN TANT QUE MODULATEURS DE L'IL-17
  申请人：JANSSEN BIOTECH INC

  公开号：WO2021222404A1

  公开（公告）日：2021-11-04

  The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

  本申请公开了具有以下公式(I)的化合物，或其药用可接受的盐，其中R1、R2、R3、R4和R5在说明书中定义，以及制造和使用所公开化合物的方法，用于治疗或改善IL-17介导的综合征、紊乱和/或疾病。
• IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
  申请人：Janssen Biotech, Inc.

  公开号：US20220402922A1

  公开（公告）日：2022-12-22

  The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
• [EN] BENZIMIDAZOLES AS MODULATORS OF IL-17<br/>[FR] BENZIMIDAZOLES UTILISÉS EN TANT QUE MODULATEURS D'IL-17
  申请人：[en]JANSSEN PHARMACEUTICA NV

  公开号：WO2023049888A1

  公开（公告）日：2023-03-30

  The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.